FDA panel backs Cubist, Durata antibiotics
This article was originally published in Scrip
Executive Summary
The FDA's Anti-Infective Drugs Advisory Committee (AIDAC) on 31 March unanimously backed approval of two investigational antibiotics from Cubist Pharmaceuticals and Durata Therapeutics as treatments for acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible Gram-positive microorganisms, including methicillin-resistant Staphylococcus aureus.